Original article

Morbimortality study of infection in patients undergoing different types of dialysis in a renal replacement therapy center

Natália Fabiane Ridão Curty a,*, Lucilene Fagundes da Silva Martins b, Carmen Antônia Sanches Ito c, Marcelo Schafranski a, Dorelayne Aparecida Brites d, César Roberto Busato a

a Universidade Estadual de Ponta Grossa, Medicine Department, Avenida General Carlos Cavalcanti 4748, CEP: 84030900 Ponta Grossa, Paraná, Brazil
b Universidade Estadual de Ponta Grossa, Pharmacy and Biochemistry Department, Brazil
c Hospital Santa Casa de Misericórdia de Ponta Grossa, Hospital Infection Control, Brazil

d Article history:
Received 7 May 2013
Accepted 18 August 2013
Available online 3 January 2014

Keywords:
Hospital infection
Morbimortality
Renal replacement therapy center
Hemodialysis
Bacteria
Sensitivity profiles

A B S T R A C T

Introduction: Renal replacement therapy is the treatment of end-stage chronic kidney disease and can be performed through dialysis catheters, arteriovenous fistulas/grafts, and peritoneal dialysis. Patients are usually immunocompromised and exposed to invasive procedures, leading to high rates of infection and increased mortality.

Objectives: To compare the prevalence of infection and related deaths, as well as the sensitivity profile of the putative bacteria in patients treated with peritoneal dialysis, arteriovenous fistula hemodialysis and catheter hemodialysis.

Methods: This is case-control study. Six hundred forty-four patients undergoing renal replacement therapy were selected. Patients were divided into three groups according to the modality of dialysis treatment: peritoneal dialysis (126 patients), arteriovenous fistula hemodialysis (326 patients), and catheter hemodialysis (192 patients).

Results: One hundred sixteen patients (18.01%) developed infection. There was a higher incidence of infection in the peritoneal dialysis group (44 patients; 34.92%; OR: 3.32; CI 95%: 2.13–5.17; p = 0.0001). In the catheter hemodialysis group, 48 patients (25%) had infection (OR: 1.88; CI 95%: 1.24–2.85; p = 0.0035). In the arteriovenous fistula hemodialysis group, 24 patients (7.36%) developed infection (OR: 0.19; CI 95%: 0.12–0.31; p = 0.0001). Five patients (4.31%) died due to infection (four in the peritoneal dialysis group and one in the catheter hemodialysis group). There were no deaths due to infection in the arteriovenous fistula hemodialysis group.

Conclusions: Peritoneal dialysis is the treatment with greater risk of infection and mortality, followed by catheter hemodialysis. The lowest risk of infection and mortality was observed in arteriovenous fistula hemodialysis group.

© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND

* Corresponding author.
E-mail address: natalia_ridao_curty@hotmail.com (N.F. Ridão Curty).
1413-8670 © 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
http://dx.doi.org/10.1016/j.bjid.2013.08.007
Introduction

Chronic kidney disease (CKD) has high prevalence and incidence worldwide, particularly in Brazil. Although the National Kidney Foundation (NKF) in 2002 has proposed staging CKD in order to slow the advance toward the functional failure of the kidneys, difficulties such as lack of early diagnosis, inadequate treatment in the early stages, delayed specialized monitoring, and the complexity of the disease lead many people to need renal replacement therapy (RRT). RRT can be implemented through hemodialysis (HD), peritoneal dialysis (PD), and renal transplantation. Each treatment has its own characteristics, advantages, disadvantages, and complications. Peritoneal dialysis allows the patient home treatment decreasing outpatient visits. Hemodialysis can be performed through a central catheter (CH) inserted in the internal jugular or subclavian vein or through an arteriovenous fistula (AVF) preferably in the upper limbs whose optimal functionality delay varies from one to three months. Nosocomial infection is one of the most serious complications and the second cause of death in dialysis patients. The risk factors that predispose to nosocomial infection in RRT may be influenced by patient characteristics, site of dialysis access, and disorders of the skin and mucous membranes; and comorbidities such as diabetes mellitus, anemia, cardiovascular disease, immunosuppression, and metabolic imbalances. Peritonitis is the most frequent infection in patients undergoing PD, and sepsisemia is the most frequent complication among patients on HD, especially when conducted through a central venous catheter. The kind of vascular access for HD has significant influence on patient survival. Catheters are associated with substantially greater risk of septicemia, hospitalization, and mortality compared to AVF. There are few studies in Brazil evaluating infection rates, the prevalent microorganisms and the susceptibility profile of bacterial infections associated with RRT. These data may be useful for empirical anti-infective therapy in these patients, as well as to better evaluate the choice of dialysis treatment aiming at preventing infections. The objective of the present study was to compare the prevalence of infection and related deaths, as well as the sensitivity profile of the putative bacteria in RRT treated patients.

Methods

This is a case-control study. The study sample consisted of 644 patients treated in the RRT outpatient center at Santa Casa de Misericordia de Ponta Grossa Hospital during a 29-month period. Patients on RRT who developed nosocomial infection (116 patients) were considered as cases. Patients who did not develop infection (528 patients) were considered as controls. Nosocomial infections were considered when the Commission of Hospital Infection Control (CHIC) identified the case as such, based on clinical features, complementary blood tests, and culture results of biological material. Unconfirmed cases of infection by the CHIC were excluded. The patients were divided into three groups according to the type of dialysis treatment: PD (116 patients), CH (192 patients), and arteriovenous fistula hemodialysis (AVH) (326 patients). The study was approved by the local ethics committee.

Statistical analysis

To compare categorical variables, two-tailed Fisher’s exact test with Bonferroni correction for multiple comparisons was used. To evaluate the effect size Odds Ratio (OR) was calculated with 95% confidence interval (CI) and its transformation in probability (p). The samples were properly tested for normality by Anderson–Darling test. The presence of outliers was checked by the Grubbs test. The statistical power of the sample was computed in each comparison. Results are presented as mean ± standard deviation (SD). Analyses, including descriptive statistics, were performed using EPI INFO program. p < 0.05 was considered statistically significant.

Results

Of the 644 patients who underwent dialysis during the study period, 116 (18.1%) developed some infection (63 male; 57.22 ± 12.76 years). One hundred fifty-six infections were reported. Seventy-one (45.51%) infections (56.14 ± 11.22 years) were in patients on PD, 60 (38.46%) infections (59.82 ± 13.33 years) in patients on CH, and 25 (16.2%) infections in patients on AVH (53.8 ± 14.7 years) (Table 1).

Comparison between groups

Of the 126 patients undergoing PD, 44 (34.92%) had at least one infection during the study period, which was significantly higher than that in the other two groups (OR: 3.32; CI 95%: 2.13–5.17; p = 0.0001). CH also showed up as a risk factor for the development of infection with 48 (25%) of the 192 infected patients (OR: 1.8824; CI 95%: 1.24–2.85; p = 0.0035). The lowest incidence of infection was observed in AVH group: 24 (7.36%) of 326 patients (OR: 0.19; CI 95%: 0.12–0.35; p = 0.0001). For all comparisons made, the statistical power was greater than 99%, with a consequent error – beta less than 1% (Table 2).

Individual comparison between groups

Comparing the groups individually, AVH turned out to be the safest method with less infections, resulting in lower incidence of morbidity when compared with CH (OR: 0.23; CI 95%: 0.14–0.40; p = 0.0001) and PD (OR: 0.14; CI 95%: 0.08–0.25; p = 0.0001). There was no statistically significant difference between the incidence of infections in the PD group and the CH group (OR: 0.62; CI 95%: 0.38–1.01; p = 0.0593). The statistical power to detect these differences was 100% in both cases, therefore no beta error (Table 3).

Deaths

Of patients infected (116), five died due to infection, with an overall mortality rate of 4.31%. There were four deaths (9.09%)
Table 1 – Patient characteristics by age and sex.

|       | PD      | CH      | AVH     | Total   |
|-------|---------|---------|---------|---------|
|       | n   | %     | n   | %     | n   | %     | n   | %     |
| Sex   |      |       |      |       |      |       |      |       |
| Male  | 21  | 47.72 | 29  | 60.41 | 13  | 54.16 | 63  | 54.31 |
| Female| 23  | 52.27 | 19  | 39.58 | 11  | 45.83 | 53  | 45.68 |
| Total | 44  | 37.93 | 48  | 41.37 | 24  | 20.68 | 116 | 100   |
| Age   | 56.14±11.22 | 59.82±13.33 | 53.8±14.70 | 57.22±12.76 | p = 0.84 |

PD, peritoneal dialysis; CH, central catheter hemodialysis; AVH, arteriovenous fistula hemodialysis.

Table 2 – Rate of infection in patients on renal replacement therapy according to the type of dialysis.

| Type of dialysis | Patients with infection n (%) | Patients without infection n (%) | OR (CI 95%)<sup>b</sup> | P<sup>c</sup> | p<sup>a</sup> | Statistical power (%) |
|------------------|--------------------------------|---------------------------------|--------------------------|------------|-------------|----------------------|
| AVH              | 24 (7.36)                      | 302 (92.63)                     | 0.19 (0.12–0.31)         | 6.12       | 0.0001<sup>1</sup> | 100                  |
| Catheter         | 48 (25)                        | 144 (75)                        | 1.88 (1.24–2.85)         | 1.53       | 0.0035<sup>2</sup> | 99.2                 |
| Peritoneal       | 44 (34.92)                     | 82 (65.07)                      | 3.32 (2.13–5.17)         | 1.30       | 0.0001<sup>1</sup> | 99.8                 |
| Total            | 116                            | 528                             | –                         | –          | –            | –                    |

<sup>a</sup> Fisher’s exact test with correction for Bonferroni multiple comparisons. Considering a significant p < 0.017.
<sup>b</sup> Odds Ratio (OR) with Confidence Interval (CI) of 95%.
<sup>c</sup> Probability (P). 1 hemodialysis by arteriovenous fistula (AVH) versus hemodialysis by catheter (CH) + peritoneal dialysis (PD). 2 CH versus AVH + DP. 3 DP versus AVH + CH. RRT = renal replace therapy. AVF = arteriovenous fistula.

Table 3 – Comparison of the infection frequency in the different groups of dialysis.

| Groups         | Patients with infection n (%) | Patients without infection n (%) | OR (CI 95%)<sup>a</sup> | P<sup>b</sup> | p<sup>c</sup> | Statistical power (%) |
|----------------|--------------------------------|---------------------------------|--------------------------|------------|-------------|----------------------|
| AVH            | 24 (7.36)                      | 302 (92.63)                     | 0.23 (0.14–0.40)         | 3.19       | 0.0001<sup>1</sup> | 100                  |
| Catheter       | 48 (25)                        | 144 (75)                        | 0.62 (0.38–1.01)         | 0.60       | 0.0593<sup>2</sup> | 100                  |
| Peritoneal     | 44 (34.92)                     | 82 (65.07)                      | 0.14 (0.08–0.25)         | 5.75       | 0.0001<sup>1</sup> | 100                  |
| Total          | 116                            | 528                             | –                         | –          | –            | –                    |

<sup>a</sup> Fisher’s exact test with Bonferroni correction for multiple comparisons. Considering significant p < 0.017.
<sup>b</sup> Odds Ratio (OR) with Confidence Interval (CI) of 95%.
<sup>c</sup> Probability (P). 1 hemodialysis by arteriovenous fistula (FAVH) versus hemodialysis by catheter (CH). 2 hemodialysis by catheter (CH) versus peritoneal dialysis (PD). 3 PD versus hemodialysis by arteriovenous fistula (AVH). AVF = arteriovenous fistula.

in PD group and one (8.2%) in CH group. No death was observed in AVH group.

Sites of infection and bacterial etiology

Microbiological tests were carried out in 151 (96.78%) patients, with infections turning out positive in 126 (80.76%). CH group was the group with the highest positivity rate (93.33%; 56/58 cultures), followed by the PD group (81.28%; 59/71 cultures) and the AVH group (52%; 13/22 cultures). The biological samples used for culture were peritoneal fluid in 46.47% of infections of PD group, blood culture in 72.41% of infections of CH group and 40.9% of infections of AVH group. Other samples used for culture were catheter secretion, dialysate fluid, cardiac valve secretion, sputum, and urine (Table 4). The most common infection in the PD group was peritonitis in

Sensitivity profile of etiologic agents

The sensitivity profiles of the main isolated bacteria are shown in Table 7. Among the most important findings, 5 (11.4%)
mecillin-resistant S. aureus (MRSA) isolates, all observed in PD group, and 7 (15.2%) meccillin-resistant SNPC infections (6 in CH group) stand out. There was no reported resistance to neither vancomycin nor rifampicin. One (5.5%) E. coli isolate from PD group was extended-spectrum β-lactamase producer (ESBL) and multidrug resistant to antimicrobials. Multidrug resistant Klebsiella pneumoniae was recovered from two isolates (40%), one from PD group and another from CH group. Isolates of Serratia spp. (5) were susceptible to most antimicrobials tested. Resistant Pseudomonas aeruginosa was observed in only one isolate (16.7%) from CH group. Carbapenem resistance was not detected. The remaining isolates were susceptible to most antibiotics tested. Overall, multidrug resistant bacterial infections were recovered from 16 (10.26%) patients: 9 (56.25%) from CH group and 7 (43.75%) from PD group, representing 14.28% and 11.86% infections, respectively, with no statistical difference (OR: 1.23; CI 95%: 0.42–3.5; p = 0.7914; statistical power of 100%). No multidrug resistant isolate was recovered from AVH group.

**Discussion**

As previously reported, PD patients had higher rate of infection compared to CH and AVH patients.9–12 Likewise, a high mortality rate (9.9%) of infected patients was observed in PD
group when compared to CH patients (2.08%). Johnson et al.\textsuperscript{13} reported a mortality rate of 7.6% and 4.2%, respectively, also showing an increased risk of death in infected PD patients. Lower rates (3.5%) of mortality in PD were reported by Barretti et al.\textsuperscript{14} Peritonitis is the main limitation of PD and is very frequent.\textsuperscript{11,13–15} In CH group, bloodstream infection is the most common site of infection. In the present study, bloodstream infection was presented in 73.33% of patients in CH group, compared to 16% in AVH group and 4.22% in PD group. These results are similar to several studies reporting 50–80% of bloodstream infections\textsuperscript{16} mostly related to the use of catheters.\textsuperscript{11,12,16} Couto et al.\textsuperscript{15} describe aseptic peritonitis, an entity found in about 10% of cases, where there is no identified etiological agent. In the present study 19.71% of negative cultures were found in PD group with clinically diagnosed peritonitis. Furthermore, culture was made in all cases with no possibility of underreporting. The most frequent infectious agents isolated were Gram positive bacteria responsible for 70.36% of all infections. Similar values are found in the study by Silva et al.\textsuperscript{6} with 60% of cases, in Asian et al.\textsuperscript{21} with 62%, and in Couto et al.\textsuperscript{15} with 67% of cases. Other studies show that the proportion of Gram positive and Gram negative bacteria is similar.\textsuperscript{17,18} S. aureus and SNPC were the most frequent pathogens isolated, as in other studies.\textsuperscript{14–15,19–21} Methicillin resistant SNPC was found in 15.2% of infections, a lower rate of resistance than the 58.4% and 100% reported by Barretti et al.\textsuperscript{14} and Britta et al.,\textsuperscript{20} respectively. The incidence of MRSA in the present study was 11.4% compared to rates of 14.3%,\textsuperscript{13,14} 22%,\textsuperscript{22,23} 30%,\textsuperscript{20} and 43.4%\textsuperscript{17} found in other studies. Gram negative organisms were responsible for 23.69% of all infections in the present study. E. coli was the most frequent with 13.33%. Seventeen of 18 cultures (94.45%) were sensitive to ceftriaxone, whereas 66.7% and 55.6% were sensitive to ciprofloxacin and cefalotin. Britta et al.\textsuperscript{20} reported a study in which E. coli had 100% resistance to these antibiotics. An isolate of E. coli was ESBL producer (5.55%), multidrug resistant, and sensitive to meropenem. As in the study by Sader et al.\textsuperscript{12} no resistance to this antibiotic was found in the present study. For K. pneumoniae 80% was sensitive to ceftriaxone and 60% to ceftazidime. Nogueira et al.\textsuperscript{24} showed 53.3% and 80% sensitivity, respectively, and Almeida et al.\textsuperscript{25} reported 34% sensitivity for both antibiotics. Serratia, Enterobacter, and Proteus were also isolated (Table 6). Non-fermentative bacilli were isolated in eight (5.92%) cultures, P. aeruginosa in six (4.44%) of which only one (16.7%) was multidrug resistant, and Acinetobacterbaumannii was recovered in two cultures. Britta et al.\textsuperscript{20} showed multidrug resistance in 50% of cases. Polymicrobial infections were observed in 3.5% of cases of PD group, a rate much lower than the 30%\textsuperscript{15} 10.7%,\textsuperscript{18} and 9.09%\textsuperscript{25} reported by other studies. In CH group polymicrobial infections were more frequently isolated (10.71%). The lower rate of resistance of the isolates in the present study translates into reduced morbidity and hospital costs.\textsuperscript{16} This finding could be attributed to the antimicrobial control policy implemented by the CHIC, which is based on quarterly updates of clinical sensitivity of local microbiota and prescription supervision of electronic medical records.

### Table 7 - Sensitivity profile of the main isolated bacteria.

| Antimicrobial          | S. aureus | SNPC | E. coli | K. pneumoniae | P. aeruginosa |
|------------------------|-----------|------|---------|---------------|--------------|
|                        | n         | s    | %       | n             | s            | %       | n         | s    | %       | n         | s    | %       |
| Azithromycin           | 44        | 32   | 72.72   | 46            | 19           | 41.30   |
| Ampicillin (Amp)       |           |      |         |               |              |         |
| Amp/Sulbactam          |           |      |         |               |              |         |
| Cefazolin              |           |      |         |               |              |         |
| Cefalotin              | 44        | 39   | 88.63   | 46            | 38           | 82.60   |
| Ceftazidime            |           |      |         |               |              |         |
| SMT + TMT              | 44        | 40   | 90.90   | 46            | 31           | 67.39   |
| Gentamicin             | 44        | 39   | 88.63   | 46            | 31           | 67.39   |
| Ciprofloxacin          | 44        | 39   | 88.63   | 46            | 34           | 73.91   |
| Amikacin               |           |      |         |               |              |         |
| Ceftriaxone            |           |      |         |               |              |         |
| Meropenem              |           |      |         |               |              |         |
| Penicillin             | 44        | 8    | 18.18   | 46            | 5            | 10.86   |
| Oxacillin              | 44        | 39   | 88.63   | 46            | 39           | 84.78   |
| Vancomycin             | 44        | 44   | 100     | 46            | 100          |         |
| Cefepime               | 16        | 16   | 100     | 5             | 4            | 80      | 5         | 100  | 83.33   |
| Aztreonam              | 16        | 16   | 100     | 5             | 4            | 80      | 5         | 100  | 83.33   |
| Erythromycin           | 44        | 32   | 72.72   | 46            | 33           | 71.73   |
| Clindamycin            | 44        | 37   | 84.09   | 46            | 32           | 69.56   |
| Chloramphenicol        | 44        | 40   | 90.90   | 46            | 44           | 95.65   |
| PIP + TZB              | 16        | 16   | 100     | 5             | 5            | 100     | 5         | 100  | 83.33   |
| Rifampin               |           |      |         |               |              |         |
| Tobramycin             | 6         | 6    | 100     |               |              |         |

### Conclusions

The present study provides evidence that the type of vascular access in RRT is an important predisposing factor for infection which, in turn, increases comorbidity and hospital costs. The AVF for hemodialysis is the safest access for RRT. These results emphasize the need for early referral program for patients with CKD regarding the indication and maturation of the dialysis method. This policy decreases morbidity, mortality, and...
hospital costs. More studies are needed, especially those that are prospective and adequately powered.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

The authors thank the clinical staff of the center of renal replacement therapy of the Santa Casa de Misericórdia de Ponta Grossa hospital who kindly agreed to collaborate with data access: nurse Karla Andréia Santos, Merluci Days, and Ms Adriana Aparecida Fabri Beneduzzi; the hospital teaching sector: Almir José Martins, Adriana Fátima Menegat Schunski and Glaucia Aparecida Alves; and the hospital infection control service: Thais Caroline Rodrigues de Oliveira.

REFERENCES

1. Wander BMG, Carmo B, Abrita RR, et al. Doença Renal Crônica: Problemas e Soluções. J Bras Nefrol. 2004;26.
2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39:1–246.
3. Black C, Sharma P, Scotland G, et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess. 2010;14:1–38.
4. NK7/DOQI clinical practice guidelines and clinical practice recommendations. Am J Kidney Dis. 2006;48:1–278.
5. Bicudo D, Batista R, Furtado GH, Sola A, Medeiros EAS. Risk factors for catheter-related bloodstream infection: a prospective multicenter study in Brazilian intensive care units. Braz J Infect Dis. 2011;15:328–33.
6. Silva LK, Bregman R, Lessi D, Leimann B, Alves MB. Ensaio sobre a cequera: mortalidade de pacientes com doença renal crônica em hemodiálise de emergência. Ciência Saúde Coletiva. 2012;17:2971–80.
7. Chaudhary K, Sangha H, Khanna R. Peritoneal dialysis first: rationale. Clin J Am Soc Nephrol. 2011;6:647–56.
8. Wang KJ, Chang YC, Liang CC, et al. Hemodialysis and peritoneal dialysis patients. Intern Med. 2012;51:1015–21.
9. Coentrão L, Santos-Araújo C, Dias C, Neto R, Pestana M. Effects of starting hemodialysis with an arteriovenous fistula or central venous catheter compared with peritoneal dialysis: a retrospective cohort study. BMC Nephrol. 2012;13:88.
10. Riella MC, Pecois-filho R. Princípios de nefrologia e distúrbios hidroeletrolíticos. 4th ed. Rio de Janeiro: Guanabara Koogan; 2003. p. 980–1013.
11. Aslam N, Bernardini J, Fried L, et al. Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients. Clin J Am Soc Nephrol. 2006;1:226–133.
12. Koch M. Comparable outcome of acute unplanned peritoneal dialysis and haemodialysis. Nephrol Dial Transplant. 2012;27:375–80.
13. Johnson DW, Dent H, Hawley CM, et al. Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis. 2009;53:290–7.
14. Barrett P, Montelli AC, Batalha JEN, Caramori JCT, Lourdes M, Cunha RS. The role of virulence factors in the outcome of staphylococcal peritonitis in CAPD patients. BMC Infect Dis. 2009;9:212.
15. Couto RC, Pedrosa TMG, Cunha AFA, Amaral DB. Infecção hospitalar e outras complicações não-infecciosa da doença: epidemiologia, controle e tratamento. 4th ed. Rio de Janeiro: Guanabara Koogan; 2009. p. 146–66, 440–455, 556–573.
16. Terra FS, Dias CAMD, Tavares FE, et al. As principais complicações apresentadas pelos pacientes renais crônicos durante as sessões de hemodiálise. Rev Bras Clin Med. 2010;8:187–92.
17. Grothe C, Belasco AGS, Bittencourt ARC, Vianna LAC, Sesso RCC, Barbosa DA. Incidência de infeção da corrente sanguínea nos pacientes submetidos à hemodiálise por cateter venoso central. Rev Latino-Am Enferm. 2010;18:1–8.
18. Lioussfi Z, Rhou H, Ezzaïtouni F, Ouezdoud N, Bayahia R, Benamar L. Péritonites infectieuses en dialyse péritona¯le continue ambulatoire au CHU de Rabat: profil bactériologique sur trois ans. Pan Afr Med J. 2012;11:41.
19. Klyutmans J. The emergence of resistant Gram-negative bacteria—are we entering the post-antibiotic era? Eur Infect Dis. 2012;6:19–21.
20. Britta EA, Amadei L, Dias JRC, Moreira RRB, Pedrinho SRF. Prevalência e perfil de sensibilidade de microorganismos isolados de materiais biológicos de pacientes submetidos a terapia renal substitutiva. Maringá: Anais da Cesumar; 2007.
21. Barros LFNT, Arênas VG, Bittencourt ARC, et al. Avaliação do tipo de curativo utilizado em cateter venoso central para hemodiálise. Acta Paul Enferm. 2009;22:481–6.
22. Govindarajulu S, Hawley CM, McDonald SP, et al. Staphylococcus aureus peritonite em pacientes em diálise peritoneal australianos: preditores, tratamento, e os resultados em 503 casos. Perit Int Dial. 2010;30:311–9.
23. Sader HS, Gales CA, Pfaller MA, et al. SENTRY-Antimicrobial Surveillance Program. Braz J Infect Dis. 2001;5:200–14.
24. Nogueira PSF, Moura ER, Costa MFM, Monteiro WMS, Brondi L. Perfil da infecção hospitalar em um hospital universitário. Rev Enferm UERJ. 2009;17:96–101.
25. Almeida PRL, Camargo NS, Arenz M, Tovo CV, Galperin B, Behar P. Peritonite bacteriana espontânea: impacto das mudanças da microbiologia. Arq Gastroenterol. 2007;44:68–72.
26. Lindsay EN, Antimicrobial resistance. Eur Infect Dis. 2011;5:92–7.